FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA Office of Acquisitions and Grants Services
Contract Value
Not provided
Codes & Classification
Solicitation Number
FDABAA-26-00123_Award
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AJ11
Additional Details
Documents1
The Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued an award notice for the FY26 FDA Broad Agency Announcement (BAA) focused on the advanced research and development of regulatory science. This procurement activity, identified by FDABAA-26-00123_Award, is designed to support innovative research initiatives that enhance the FDA’s regulatory mission, particularly in the field of biotechnology (excluding nanobiotechnology), as classified under NAICS code 541714.
The scope of this BAA encompasses a wide range of advanced research and development projects aimed at strengthening the scientific foundation for regulatory decision-making. The intended outcomes are to foster scientific advancements that directly inform and improve the FDA’s regulatory processes, ensuring the safety, efficacy, and quality of products overseen by the agency. The announcement has resulted in a total of 53 awards, reflecting the FDA’s commitment to supporting a diverse portfolio of research efforts in regulatory science.
Key requirements and objectives for this procurement include the delivery of research outcomes that address critical regulatory science challenges. Awardees are expected to provide innovative solutions, methodologies, or technologies that can be translated into practical regulatory applications. The expected deliverables will vary by project but are unified by the goal of advancing the FDA’s capacity to evaluate and regulate emerging biotechnologies.
The place of performance for these awards is Silver Spring, Maryland, which serves as a central hub for FDA operations. The contracting activity is managed by the FDA Office of Acquisitions and Grants Services, a federal office responsible for overseeing the acquisition and grant processes for the agency. The primary point of contact for this announcement is Ian Weiss, who can be reached at [email protected] or by phone at 301-796-5728.
This procurement is classified under Product Service Code AJ11, which pertains to general research and development in the life sciences. There are no set-aside requirements associated with this announcement, indicating that the opportunity was open to all eligible entities without restrictions based on business size or socioeconomic status.
Contractors considering participation in future BAAs of this nature should note the FDA’s emphasis on high-impact research that directly supports regulatory science objectives. The agency seeks partners with demonstrated expertise in biotechnology research and a strong track record of delivering actionable scientific insights. The consistent elements throughout the contract lifecycle include a focus on regulatory science advancement, adherence to FDA research priorities, and collaboration with the FDA’s scientific and regulatory staff.
For further details, interested parties are encouraged to review the official notice and its attachments via the SAM.gov opportunity listing at https://sam.gov/opp/572eca56bbbe4deb895f8a4bdbc8d8a1/view.